Sep 03, 2015 - Novartis (NVS) launched Zarxio (biosimilar version of Amgen's Neupogen) in the U.S., which became the first FDA-approved biosimilar to be launched in the country.
Sep 02, 2015 - Bristol-Myers Squibb Company (BMY) and its partner AbbVie (ABBV) announced that the BLA for Empliciti has been accepted with priority review by the FDA.
Sep 01, 2015 - Perrigo Company plc (PRGO) announced that it has acquired a leading U.S. OTC scar management brand, ScarAway, from Enaltus.
Sep 01, 2015 -
Sep 01, 2015 - ITCA-650 should reach the market in 2017 and has the potential to change competitive dynamics in type 2 diabetes space.
Aug 31, 2015 - Top gainers, as of 5.25 p.m.: [[TRVN]] +41.0%. [[DBVT]] +4.4%. [[SUNE]] +4.2%. [[JAKK]] +2.4%. [[NVO]] +1.1%. Top losers, as of 5.25p.m.: [[ACI]] -8.7%. [[
Aug 31, 2015 - Bristol-Myers Squibb Company (BMY) announced that it has entered into a research collaboration and license agreement with QIMR Berghofer Medical Research Institute.
Aug 31, 2015 - Novo Nordisk stock is a potential outperformer that is an impressive choice for growth investors, making it a security that you need to keep on your radar in the near term
Aug 28, 2015 - Another day, another diabetes development. In the GLP-1 alternative delivery game Intarcia Therapeutics gained an edge last week with its ITCA 650 implant, but Novo Nordisk (NYSE:NVO) is close behind
Aug 27, 2015 - Novo Nordisk (NVO) announced that it intends to start the phase IIIa PIONEER program on once-daily oral semaglutide for the treatment of type II diabetes.